From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area

Inflamm Bowel Dis. 2020 Jun 24;izaa162. doi: 10.1093/ibd/izaa162. Online ahead of print.

Jordan E Axelrad 1, Lisa Malter 1, Simon Hong 1, Shannon Chang 1, Brian Bosworth 1, David Hudesman 1


Author information

  • 1Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology and Hepatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY.


Background: We aimed to characterize patients with inflammatory bowel disease (IBD) and novel coronavirus disease 2019 (COVID-19).

Methods: We performed a case series of patients with IBD and confirmed or highly suspected COVID-19 to assess rates of severe outcomes.

Results: We identified 83 patients with IBD with confirmed (54%) or highly suspected (46%) COVID-19. The overall hospitalization rate was 6%, generally comprising patients with active Crohn's disease or older men with comorbidities, and 1 patient expired.

Discussion: In this series of patients with IBD, severe outcomes of COVID-19 were rare and comparable to similarly aged individuals in the general population.

© Copyright 2013-2023 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.